Difference between revisions of "Research budget in pharmaceutical industry"
Jump to navigation
Jump to search
Peter Friedl (talk | contribs) |
Peter Friedl (talk | contribs) |
||
| Line 16: | Line 16: | ||
* [1] [http://www.globalissues.org/article/52/pharmaceutical-corporations-and-medical-research Pharmaceutical Corporations and Medical Research] - article on Global Issues | * [1] [http://www.globalissues.org/article/52/pharmaceutical-corporations-and-medical-research Pharmaceutical Corporations and Medical Research] - article on Global Issues | ||
* [2] [http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf R&D in the Pharmaceutical Industry] - a Congressional Budget Office Study | |||
Revision as of 19:33, 15 September 2009
This page is under construction and edited by Peter Friedl EMBA09. In case of any questions/remarks, feel free to contact me
Description:
A short description of the driving force.
Enablers:
Factors which strengthen this driving force. (these are actually other driving forces, and you can link to them in the wiki!)
Inhibitors:
Factors which weaken this driving force. (these are actually other driving forces, and you can link to them in the wiki!)
Paradigms:
Changes in ways of thinking about the world due to the driving force.
Experts:
Sources for additional information about this driving force. (if you have found people, put the links to them)
Timing:
Dates for key milestones in the development of the driving force.
Web Resources:
- [1] Pharmaceutical Corporations and Medical Research - article on Global Issues
- [2] R&D in the Pharmaceutical Industry - a Congressional Budget Office Study